vs
Side-by-side financial comparison of BADGER METER INC (BMI) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
BADGER METER INC is the larger business by last-quarter revenue ($234.1M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 14.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 9.2%).
Badger Meter Inc. is a leading global provider of flow measurement and control solutions, serving water utilities, industrial, commercial, and residential customer segments. Its core offerings include smart water meters, IoT-enabled usage monitoring systems, and supporting software that help clients track resource consumption, cut waste, and boost operational efficiency, with key markets spanning North America, Europe, and the Asia-Pacific region.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BMI vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $234.1M | $168.4M |
| Net Profit | $33.6M | — |
| Gross Margin | 39.7% | — |
| Operating Margin | 18.4% | 50.6% |
| Net Margin | 14.3% | — |
| Revenue YoY | 14.1% | 143.7% |
| Net Profit YoY | 9.3% | — |
| EPS (diluted) | $1.13 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $234.1M | $168.4M | ||
| Q3 25 | $222.2M | $87.3M | ||
| Q2 25 | $238.1M | $82.4M | ||
| Q1 25 | $222.2M | $65.0M | ||
| Q4 24 | $205.2M | $69.1M | ||
| Q3 24 | $208.4M | $51.6M | ||
| Q2 24 | $216.7M | $73.8M | ||
| Q1 24 | $196.3M | $137.7M |
| Q4 25 | $33.6M | — | ||
| Q3 25 | $35.1M | $-31.3M | ||
| Q2 25 | $34.6M | $-12.7M | ||
| Q1 25 | $38.4M | $-40.5M | ||
| Q4 24 | $30.7M | — | ||
| Q3 24 | $32.0M | $-29.5M | ||
| Q2 24 | $33.1M | $-61.9M | ||
| Q1 24 | $29.1M | $61.0M |
| Q4 25 | 39.7% | — | ||
| Q3 25 | 43.1% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 42.9% | — | ||
| Q4 24 | 40.3% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | 39.4% | — | ||
| Q1 24 | 39.3% | — |
| Q4 25 | 18.4% | 50.6% | ||
| Q3 25 | 20.7% | -11.4% | ||
| Q2 25 | 18.8% | 8.6% | ||
| Q1 25 | 22.2% | -34.0% | ||
| Q4 24 | 19.1% | -6.4% | ||
| Q3 24 | 19.5% | -31.0% | ||
| Q2 24 | 19.2% | 3.5% | ||
| Q1 24 | 18.6% | 52.5% |
| Q4 25 | 14.3% | — | ||
| Q3 25 | 15.8% | -35.9% | ||
| Q2 25 | 14.5% | -15.4% | ||
| Q1 25 | 17.3% | -62.2% | ||
| Q4 24 | 15.0% | — | ||
| Q3 24 | 15.4% | -57.2% | ||
| Q2 24 | 15.3% | -83.9% | ||
| Q1 24 | 14.8% | 44.3% |
| Q4 25 | $1.13 | $0.32 | ||
| Q3 25 | $1.19 | $-0.16 | ||
| Q2 25 | $1.17 | $-0.06 | ||
| Q1 25 | $1.30 | $-0.21 | ||
| Q4 24 | $1.04 | $-0.14 | ||
| Q3 24 | $1.08 | $-0.15 | ||
| Q2 24 | $1.12 | $-0.33 | ||
| Q1 24 | $0.99 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $713.3M | $-302.0M |
| Total Assets | $973.6M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | — | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | $713.3M | $-302.0M | ||
| Q3 25 | $702.5M | $-451.4M | ||
| Q2 25 | $677.6M | $-433.5M | ||
| Q1 25 | $641.7M | $-426.2M | ||
| Q4 24 | $606.2M | $-388.7M | ||
| Q3 24 | $591.2M | $-370.2M | ||
| Q2 24 | $563.1M | $-344.2M | ||
| Q1 24 | $535.6M | $-294.3M |
| Q4 25 | $973.6M | $465.9M | ||
| Q3 25 | $978.3M | $364.0M | ||
| Q2 25 | $936.4M | $347.1M | ||
| Q1 25 | $899.6M | $324.0M | ||
| Q4 24 | $816.4M | $343.8M | ||
| Q3 24 | $802.9M | $314.1M | ||
| Q2 24 | $781.3M | $352.3M | ||
| Q1 24 | $743.5M | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $54.8M | $45.2M |
| Free Cash FlowOCF − Capex | $50.8M | — |
| FCF MarginFCF / Revenue | 21.7% | — |
| Capex IntensityCapex / Revenue | 1.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.63× | — |
| TTM Free Cash FlowTrailing 4 quarters | $169.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.8M | $45.2M | ||
| Q3 25 | $51.3M | $-4.3M | ||
| Q2 25 | $44.6M | $-31.4M | ||
| Q1 25 | $33.0M | $-22.6M | ||
| Q4 24 | $52.1M | $-35.0M | ||
| Q3 24 | $45.1M | $-35.3M | ||
| Q2 24 | $36.4M | $-7.2M | ||
| Q1 24 | $21.5M | $53.8M |
| Q4 25 | $50.8M | — | ||
| Q3 25 | $48.2M | — | ||
| Q2 25 | $40.6M | — | ||
| Q1 25 | $30.1M | — | ||
| Q4 24 | $47.4M | — | ||
| Q3 24 | $42.0M | $-35.5M | ||
| Q2 24 | $34.1M | $-7.3M | ||
| Q1 24 | $18.8M | $53.8M |
| Q4 25 | 21.7% | — | ||
| Q3 25 | 21.7% | — | ||
| Q2 25 | 17.1% | — | ||
| Q1 25 | 13.5% | — | ||
| Q4 24 | 23.1% | — | ||
| Q3 24 | 20.1% | -68.7% | ||
| Q2 24 | 15.7% | -9.9% | ||
| Q1 24 | 9.6% | 39.0% |
| Q4 25 | 1.7% | 0.0% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 1.7% | 0.0% | ||
| Q1 25 | 1.3% | 0.0% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 1.5% | 0.3% | ||
| Q2 24 | 1.1% | 0.1% | ||
| Q1 24 | 1.4% | 0.1% |
| Q4 25 | 1.63× | — | ||
| Q3 25 | 1.46× | — | ||
| Q2 25 | 1.29× | — | ||
| Q1 25 | 0.86× | — | ||
| Q4 24 | 1.70× | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 0.74× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMI
| Transferred At Point In Time | $198.6M | 85% |
| Transferred Over Time | $22.1M | 9% |
| Other | $13.4M | 6% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
